Literature DB >> 10537199

Antibodies to a synthetic 1-9-N-terminal amino acid fragment of mature pediocin PA-1: sensitivity and specificity for pediocin PA-1 and cross-reactivity against Class IIa bacteriocins.

J M Martínez1, M I Martínez, C Herranz, A Suárez, M F Fernández, L M Cintas, J M Rodríguez, P E Hernández.   

Abstract

Polyclonal antibodies specific for pediocin PA-1 (PedA1) were generated by immunization of rabbits with a chemically synthesized 1-9-N-terminal amino acid fragment of this bacteriocin (PH1) conjugated to the carrier protein keyhole limpet haemocyanin (KLH). The PH1 fragment holds a highly conserved amino acid sequence with closely related Class IIa bacteriocins. The sensitivity and specificity of the PH1-KLH-generated rabbit polyclonal antibodies were evaluated by the development of various ELISAs, such as a non-competitive indirect ELISA (NCI-ELISA), a competitive indirect ELISA (CI-ELISA), a competitive direct ELISA (CD-ELISA) and a sandwich ELISA (S-ELISA), and by protein slot-blotting and Western blotting. NCI- and CI-ELISA were valuable for detecting the existence of PedA1-specific antibodies in the sera of immunized rabbits. The limit of detection of PedA1 in MRS medium was found to be 0.5 microg ml(-1) in NCI-ELISA, while CI-ELISA on plates coated with purified PedA1 increased the affinity of the PH1-KLH-generated antibodies for PedA1; the limit of detection of PedA1 was less than 0.01 microg ml(-1) and 50% binding inhibition was achieved with 0.1 microg PedA1 ml(-1). Similarly, the limits of detection of PedA1 in MRS medium were found to be 5 microg ml(-1) by protein slot-blotting and 0.01 microg ml(-1) by Western blotting. Most importantly, PH1-KLH-generated polyclonal antibodies detected the presence of PedA1 in the supernatants of the producing strains of Pediococcus acidilactici 347, Z102, A172, X13 and P20, with no reactivity or negligible immunoreactivity with the supernatants of other lactic acid bacteria producing or not producing closely related or different bacteriocins. The approaches taken for the selection of the bacteriocin peptide fragment, the generation of antibodies and the development of immunoassays could prove useful for the generation and evaluation of antibodies of adequate specificity for other bacteriocins of interest in the food industry.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10537199     DOI: 10.1099/00221287-145-10-2777

Source DB:  PubMed          Journal:  Microbiology        ISSN: 1350-0872            Impact factor:   2.777


  5 in total

1.  Immunodetection of the bacteriocin lacticin RM: analysis of the influence of temperature and Tween 80 on its expression and activity.

Authors:  Tomer Keren; Merav Yarmus; Galia Halevy; Roni Shapira
Journal:  Appl Environ Microbiol       Date:  2004-04       Impact factor: 4.792

2.  Immunochemical characterization of temperature-regulated production of enterocin L50 (EntL50A and EntL50B), enterocin P, and enterocin Q by Enterococcus faecium L50.

Authors:  Raquel Criado; Jorge Gutiérrez; María Martín; Carmen Herranz; Pablo E Hernández; Luis M Cintas
Journal:  Appl Environ Microbiol       Date:  2006-10-20       Impact factor: 4.792

3.  Heterologous coproduction of enterocin A and pediocin PA-1 by Lactococcus lactis: detection by specific peptide-directed antibodies.

Authors:  J M Martínez; J Kok; J W Sanders; P E Hernández
Journal:  Appl Environ Microbiol       Date:  2000-08       Impact factor: 4.792

4.  Generation and utilization of polyclonal antibodies to a synthetic C-terminal amino acid fragment of divercin V41, a class IIa bacteriocin.

Authors:  Christelle Richard; Djamel Drider; Ismael Fliss; Sandra Denery; Herve Prevost
Journal:  Appl Environ Microbiol       Date:  2004-01       Impact factor: 4.792

5.  Assessment of anti-plasmodial activity of non-hemolytic, non-immunogenic, non-toxic antimicrobial peptides (AMPs LR14) produced by Lactobacillus plantarum LR/14.

Authors:  Ruchi Gupta; Vinoth Rajendran; Prahlad C Ghosh; Sheela Srivastava
Journal:  Drugs R D       Date:  2014-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.